Page 10 - Sanket Koul

DLF Q3 FY26 results: PAT up 13.6%, revenue rises 42% on high net income

Realty major states gross zero debt on high net cash position

Zydus Lifesciences launches cancer drug Nivolumab's biosimilar in India

Move comes just months before nivolumab patent expiry in India on May 2, 2026

Budget 2026: Developers demand targeted tax reforms to spur housing demand

Ahead of Budget 2026, realtors seek higher home loan tax deductions, a wider affordable housing definition, and dispute-resolution reforms to revive housing demand

CDSCO flags 7 drugs as spurious, 167 fail quality tests in Dec 2025

CDSCO has flagged seven drug batches as spurious and listed 167 others as not of standard quality in its December 2025 surveillance, covering common medicines for BP, pain and allergies

Centre halves review period for applications to conduct new drug trials

The health ministry has amended the NDCT Rules to cut approval timelines for new drug trials and testing by half, aiming to speed up innovation while easing regulatory processes for most applications

Dr Reddy's Q3 PAT down 14% Y-o-Y on low Lenalidomide sales in US

Dr Reddy's Laboratories reported a sharp fall in December-quarter profit as declining Lenalidomide sales in the US weighed on earnings, even as India revenues and branded businesses remained resilient

Elan Group awards ₹840 crore construction contract to Tata Projects

Elan Group awards an Rs 840 crore construction contract to Tata Projects for its ultra-luxury residential project 'Elan-The Statement' in Sector 49, Gurugram

High demand for luxury units drives housing segment premiumisation

Units priced ₹1 crore and above increase market share to 63% of total units sold in 2025

JB Pharma Q3 PAT up 22%, revenue rises 11% on better domestic performance

JB Pharma reports a 22% rise in Q3 FY26 profit as strong growth in domestic and international formulations offsets flat CDMO revenues

Residential assets lead as Gurugram attracts ₹86K cr investments in 2025

With ₹86,588 crore in projects cleared in 2025, Gurugram cements its place as India's hottest real estate hub-spanning premium homes, IT parks and mass housing

NEET PG cut-off slashed to zero percentile to fill over 18,000 vacant seats

Revised criteria for reserved categories; doctor bodies criticise the move

Elie Saab forays into Indian branded residence market with M3M group

Elie Saab to open first retail store this year

Nifty Realty falls 1.22% as developers fear missing FY26 sales guidance

Demand slowdown, buyers getting priced out of affordable housing, reflecting in FY26 numbers

Centre deploys team after 2 suspected Nipah cases identified in West Bengal

Centre deployed a national outbreak response team and activated emergency protocols after two suspected Nipah virus cases were detected in West Bengal

Educational institutions' income to rise 11-13% in FY26, FY27: Crisil

The report added that operating margins are expected to remain steady at 27 to 28 per cent as these institutions will incur higher staff salaries and other related costs

Bhumika Realty raises ₹170 cr to fund mixed-use project in Faridabad

Bhumika Realty raises ₹170 crore from Aditya Birla Sun Life AMC-BGO credit platform to fund its ₹700-crore mixed-use project in Faridabad

Suraksha Group completes 6K homes at Jaypee's stalled Wish Town projects

Suraksha Group completes nearly 6,000 homes across 63 towers at Noida's Wish Town, securing OCs for over 3,100 units after Jaypee Infratech takeover

Branded residences market likely to grow 60% by 2027 on global push

India's branded residences boom is gathering pace, with global luxury names and rising wealth set to drive a 60% jump in projects by 2027

Signature Global Q3 sales bookings fall 27% on lower housing sales

Signature Global's Q3 FY26 sales bookings fell 27% to ₹2,020 crore as housing demand softened and delayed project launches limited festive-season momentum

Rabies vaccine sales hit 5-year high in 2025 amid rise in dog bite cases

According to data from market research firm Pharmarack, the combined number of ARV and immunoglobulin vaccines sold in 2025 reached 8,510,000 units - the highest in five years